Carlo Vancheri

Nintedanib in patients with progressive fibrosing interstitial lung diseases—subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial

Athol U. Wells, Kevin R. Flaherty, Kevin K. Brown et al. · The Lancet Respiratory Medicine · 2020 · 522 citations · Full text

Inbuild Trial, Parallel-group Trial, Advanced Lung Disease +5

Effect of pirfenidone on proliferation, TGF-β-induced myofibroblast differentiation and fibrogenic activity of primary human lung fibroblasts

Enrico Conte, Elisa Gili, Evelina Fagone et al. · European Journal of Pharmaceutical Sciences · 2014 · 351 citations

Fibrosis, Tissue Development, Inflammatory Lung Disease +10

Progressive fibrosing interstitial lung disease: clinical uncertainties, consensus recommendations, and research priorities

Peter M. George, Paolo Spagnolo, Michael Kreuter et al. · The Lancet Respiratory Medicine · 2020 · 332 citations · Full text

Research Priorities, Antifibrotic Therapy, Fibrosis +9

Nintedanib with Add-on Pirfenidone in Idiopathic Pulmonary Fibrosis. Results of the INJOURNEY Trial

Carlo Vancheri, Michael Kreuter, Luca Richeldi et al. · American Journal of Respiratory and Critical Care Medicine · 2017 · 286 citations

Mitotic signaling by β‐amyloid causes neuronal death

Agata Copani, Fabrizio Condorelli, Antonello Caruso et al. · The FASEB Journal · 1999 · 249 citations

Apoptosis, Cell Death, Cell Cycle +16